tbuckley/cabot-search huggingface dataset:
Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges
Authors: Andrea Cignarella, Gian Paolo Fadini, Chiara Bolego, Lucia Trevisi, Carlotta Boscaro, Viola Sanga, Teresa Maria Seccia, Antonio Rosato, Gian Paolo Rossi, Matthias Barton
Journal: Cardiovascular Research (2021)

Vasoactive molecules, such as vascular endothelial growth factor (VEGF) and endothelins, share cytokine-like activities and regulate endothelial cell (EC) growth, migration, and inflammation. Some endothelial mediators and their receptors are targets for currently approved angiogenesis inhibitors, drugs that are either monoclonal antibodies raised towards VEGF, or inhibitors of vascular receptor protein kinases and signalling pathways. Pharmacological interference with the protective functions of ECs results in a similar spectrum of adverse effects. Clinically, the most common side effects of VEGF signalling pathway inhibition include an increase in arterial pressure, left ventricular dysfunction facilitating the development of heart failure, thromboembolic events including pulmonary embolism and stroke, and myocardial infarction. Sex steroids, such as androgens, progestins, and oestrogens and their receptors (ERα, ERβ, GPER; PR-A, PR-B; AR) have been identified as important modifiers of angiogenesis, and sex differences have been reported for anti-angiogenic drugs. This review article discusses the current challenges clinicians are facing with regard to angiogenesis inhibitor therapy, including the need to consider sex differences affecting clinical efficacy and safety. We also propose areas for future research taking into account the role of sex hormone receptors and sex chromosomes. Development of new sex-specific drugs with improved target- and cell-type selectivity likely will open the way to personalized medicine in men and women requiring anti-angiogenic therapy to reduce adverse effects and to improve therapeutic efficacy.
Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification
Authors: Sidsel C. Lindgaard, Zsófia Sztupinszki, Emil Maag, Inna M. Chen, Astrid Z. Johansen, Benny V. Jensen, Stig E. Bojesen, Dorte L. Nielsen, Carsten P. Hansen, Jane P. Hasselby, Kaspar R. Nielsen, Zoltan Szallasi, Julia S. Johansen
Journal: Clinical Cancer Research (2021)

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. Most patients are diagnosed at an advanced stage where curative surgery is not an option. The aim of this study was to identify a panel of circulating proteins that could distinguish patients with PDAC from non-PDAC individuals. Experimental Design: We investigated 92 proteins known to be involved in inflammation, development, and progression of PDAC using the Olink immuno-oncology panel in serum samples from 701 patients with PDAC (stage I–IV), 102 patients with nonmalignant pancreatic diseases, and 180 healthy blood donors. Patients were included prospectively between 2008 and 2018. Plasma carbohydrate antigen 19-9 (CA19-9) was measured in all samples. The protein panels with the best diagnostic performances were developed by two bioinformaticians working independently, using LASSO and Ridge regression models. Results: Two panels of proteins (index I, containing 9 proteins + CA19-9, and index II, containing 23 proteins + CA19-9) were identified. Index I was able to discriminate patients with PDAC from all patients with non-PDAC, with a ROC AUC value of 0.92 [95% confidence interval (CI), 0.89–0.96] in the discovery cohort and 0.92 (95% CI, 0.87–0.97) in the replication cohort. For index II, the AUC value was 0.96 (95% CI, 0.95–0.98) in the discovery cohort and 0.93 (95% CI, 0.90–0.96) in the replication cohort. All nine serum proteins of index I were found in index II. Conclusions: This study identified two circulating protein indices with the potential to discriminate between individuals with and without PDAC.
Keith Llewellyn Rogers
Authors: Jeremy Rogers, Ewa Rogers
Journal: BMJ (2021)

The only son of television pioneer Keith Dudley Ulysses Rogers OBE and his wife, Gladys Evans, Keith Llewellyn Rogers was raised in pre-war Radlett before boarding at Llandovery School from age 9. After house jobs and three years’ national service in Minden, Germany, he returned to the Middlesex Hospital before taking a post in the North London Transfusion Service.

In 1970 Keith became director of the South London Blood Transfusion Centre in its new premises in Tooting, serving between 60 and 70 hospitals across the South-east and South-west Thames regions and with eight daily donor sessions collecting the weekly requirement of around 5000 donations. For the following 20 years he drove the centre through the modernisations and innovations …
John Michael Welchman
Authors: Jenty Young
Journal: BMJ (2021)

John Michael Welchman followed his father and grandfather into medicine. He interrupted his studies to serve in the second world war as a Hurricane pilot in North Africa for the SAAF. He then returned to the University of the Witwatersrand and after qualifying joined Baragwanath Hospital as house physician and then became house surgeon at Johannesburg General Hospital. In 1953 he joined …
P78.04 Efficacy and Safety Analysis of Atezolizumab Monotherapy in Patients With Non-Small Cell Lung Cancer
Authors: K. Komiya, S. Ogusu, C. Nakashima, T. Nakamura, K. Nakatomi, E. Sasaki, N. Sueoka-Aragane
Journal: Journal of Thoracic Oncology (2021)
Abstract 14240: Increased Blood Pressure Was Associated With Prolonged Electrocardiographic Tpeak-Tend Interval in a General Chinese Population
Authors: Tingting Lv, Yifang Yuan, Huijuan Li, Jing Yang, Lingyun Kong, Jiayu Wang, Zhaoguo Zhang, Xinjie Li, Yingxian Sun, Xuewen Li, Zheng Zhang, Xiaoshu Cheng, Lirong Wu, Xuerui Tan, Bing Han, Yanfang Wang, Hua Li, Yangfeng Wu, Jihong Guo, Ping Zhang
Journal: Circulation (2019)

Introduction: Electrocardiographic Tpeak-Tend interval (Tpe) reflects the dispersion of ventricular repolarization. Prolonged Tpe was observed in newly diagnosed hypertensive patients in recent stu...
Linked Colour imaging for the detection of polyps in patients with Lynch syndrome: a multicentre, parallel randomised controlled trial
Authors: Britt B S L Houwen, Yark Hazewinkel, María Pellisé, Liseth Rivero-Sánchez, Francesc Balaguer, Raf Bisschops, Sabine Tejpar, Alessandro Repici, D Ramsoekh, Maarten A J M Jacobs, Ramon-Michel M Schreuder, Michal Filip Kaminski, Maria Rupinska, Pradeep Bhandari, Martijn G H van Oijen, Lianne Koens, Barbara A J Bastiaansen, Kristien M Tytgat, Paul Fockens, Jasper L A Vleugels, E Dekker
Journal: Gut (2021)

Objective Despite regular colonoscopy surveillance, colorectal cancers still occur in patients with Lynch syndrome. Thus, detection of all relevant precancerous lesions remains very important. The present study investigates Linked Colour imaging (LCI), an image-enhancing technique, as compared with high-definition white light endoscopy (HD-WLE) for the detection of polyps in this patient group. Design This prospective, randomised controlled trial was performed by 22 experienced endoscopists from eight centres in six countries. Consecutive Lynch syndrome patients ≥18 years undergoing surveillance colonoscopy were randomised (1:1) and stratified by centre for inspection with either LCI or HD-WLE. Primary outcome was the polyp detection rate (PDR). Results Between January 2018 and March 2020, 357 patients were randomised and 332 patients analysed (160 LCI, 172 HD-WLE; 6 excluded due to incomplete colonoscopies and 19 due to insufficient bowel cleanliness). No significant difference was observed in PDR with LCI (44.4%; 95% CI 36.5% to 52.4%) compared with HD-WLE (36.0%; 95% CI 28.9% to 43.7%) (p=0.12). Of the secondary outcome parameters, more adenomas were found on a patient (adenoma detection rate 36.3%; vs 25.6%; p=0.04) and a colonoscopy basis (mean adenomas per colonoscopy 0.65 vs 0.42; p=0.04). The median withdrawal time was not statistically different between LCI and HD-WLE (12 vs 11 min; p=0.16). Conclusion LCI did not improve the PDR compared with HD-WLE in patients with Lynch syndrome undergoing surveillance. The relevance of findings more adenomas by LCI has to be examined further. Trial registration number NCT03344289 .
P15.02 Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCLC
Authors: S. Puri, S. Patel, A. Chalmers, K. Kerrigan, E. Loertscher, S. George, K. Boucher, W. Akerley
Journal: Journal of Thoracic Oncology (2021)
Immune-mediated vincristine-induced neuropathy: Unlocking therapies
Authors: Masha G. Savelieff, Eva L. Feldman
Journal: The Journal of Experimental Medicine (2021)

Vincristine-induced peripheral neuropathy (VIPN) is a prevalent and painful complication in cancer patients that lacks effective treatments. In this issue of JEM, Starobova et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20201452) report that VIPN is driven by innate immune system activation, a discovery that unlocks immunotherapies as potential treatments.
P41.04 The SUMMIT Study: Pulmonary Nodule and Incidental Findings in the First 10,000 Participants of a Population-Based Low-Dose CT Screening Study
Authors: C. Horst, J. Dickson, S. Tisi, H. Hall, P. Verghese, A. Mullin, L. Farrelly, C. Levermore, K. Gyertson, C. Clarke, B. Allen, S. Hamilton, A. Hartman, A. Nair, A. Devaraj, A. Hackshaw, S. Janes
Journal: Journal of Thoracic Oncology (2021)
P14.24 Evolution of TCR Clonality during Chemoradiation and Durvalumab as Predictors of Survival in Stage 3 NSCLC
Authors: S. Lau, S. Soleimani, S. Wong, B. Wang, S. Pedersen, D. Patel, P. Bradbury, G. Liu, N. Leighl, M. Tsao, L. Siu, S. Bratman, P. Ohashi, T. Pugh, F. Shepherd, A. Sacher
Journal: Journal of Thoracic Oncology (2021)
Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study
Authors: Hye Yun Park, Yoosoo Chang, Danbee Kang, Yun Soo Hong, Di Zhao, Jiin Ahn, Sun Hye Shin, Dave Singh, Eliseo Guallar, Juhee Cho, Seungho Ryu
Journal: European Respiratory Journal (2021)

Aim The impact of blood eosinophil counts on the development of chronic obstructive lung disease (COPD) is unknown. We investigated whether a higher blood eosinophil count was associated with the risk of developing obstructive lung disease (OLD) in a large cohort of men and women free from lung disease at baseline. Methods This was a cohort study of 359 456 Korean adults without a history of asthma and without OLD at baseline who participated in health screening examinations including spirometry. OLD was defined as pre-bronchodilator forced expiratory volume in 1 s (FEV 1 )/forced vital capacity (FVC) &lt;0.7 and FEV 1 &lt;80% predicted. Results After a median (interquartile range) follow-up of 5.6 (2.9–9.2) years, 5008 participants developed incident OLD (incidence rate 2.1 (95% CI 2.1–2.2) per 1000 person-years). In the fully adjusted model, the hazard ratios for incident OLD comparing eosinophil counts of 100– &lt;200, 200– &lt;300, 300– &lt;500 and ≥500 versus &lt;100 cells·μL −1 were 1.07 (95% CI 1.00–1.15), 1.30 (95% CI 1.20–1.42), 1.46 (95% CI 1.33–1.60) and 1.72 (95% CI 1.51–1.95), respectively (p trend &lt;0.001). These associations were consistent in clinically relevant subgroups, including never-, ex- and current smokers. Conclusion In this large longitudinal cohort study, blood eosinophil counts were positively associated with the risk of developing of OLD. Our findings indicate a potential role of the eosinophil count as an independent risk factor for developing COPD.
P76.62 RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC
Authors: A. Saltos, C. Baik, R.E. Sanborn, E. Shum, C. Kim, R. Hall, M.J. Fidler, C.A. Shu, G. Otterson, J. Patel, K. Wong, N. Hanna, J. Gray, J. Heymach, X. Le
Journal: Journal of Thoracic Oncology (2021)
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension
Authors: Samantha Cruz Rivera, Xiaoxuan Liu, An-Wen Chan, Alastair K Denniston, Melanie J Calvert
Journal: BMJ (2020)

Abstract The SPIRIT 2013 (The Standard Protocol Items: Recommendations for Interventional Trials) statement aims to improve the completeness of clinical trial protocol reporting, by providing evidence-based recommendations for the minimum set of items to be addressed. This guidance has been instrumental in promoting transparent evaluation of new interventions. More recently, there is a growing recognition that interventions involving artificial intelligence need to undergo rigorous, prospective evaluation to demonstrate their impact on health outcomes. The SPIRIT-AI extension is a new reporting guideline for clinical trials protocols evaluating interventions with an AI component. It was developed in parallel with its companion statement for trial reports: CONSORT-AI. Both guidelines were developed using a staged consensus process, involving a literature review and expert consultation to generate 26 candidate items, which were consulted on by an international multi-stakeholder group in a 2-stage Delphi survey (103 stakeholders), agreed on in a consensus meeting (31 stakeholders) and refined through a checklist pilot (34 participants). The SPIRIT-AI extension includes 15 new items, which were considered sufficiently important for clinical trial protocols of AI interventions. These new items should be routinely reported in addition to the core SPIRIT 2013 items. SPIRIT-AI recommends that investigators provide clear descriptions of the AI intervention, including instructions and skills required for use, the setting in which the AI intervention will be integrated, considerations around the handling of input and output data, the human-AI interaction and analysis of error cases. SPIRIT-AI will help promote transparency and completeness for clinical trial protocols for AI interventions. Its use will assist editors and peer-reviewers, as well as the general readership, to understand, interpret and critically appraise the design and risk of bias for a planned clinical trial.
HSR21-059: Telehealth is Here—Are Patients Ready for It? An Analysis of Technological Knowledge in Cancer Patients
Authors: Jeremie M.P. Lever, Ahmer Irfan, Mona Fouad, Barry Sleckman, J. Bart Rose, Thomas N. Wang, Daniel I. Chu, Sushanth Reddy
Journal: Journal of the National Comprehensive Cancer Network (2021)

Background: The COVID-19 pandemic has led to the rapid expansion of telehealth use. Telehealth has the potential to improve access for underserved populations who live far distances from well-equipped medical centers. This healthcare modality will likely be particularly important for patients with cancer. We hypothesized that there are disparities in the resources available to utilize telehealth and sought to study patient access and knowledge of associated technologies. Methods: We conducted a single-center cross-sectional survey study of patients at an NCCN-designated comprehensive cancer center over a two-month period. Demographics, education, internet, and cell phone access were assessed. Participant technological knowledge was determined with a validated 10-question quiz of terms regarding computers and the internet. Income was extrapolated using IRS data for individual zip codes. Analysis was performed using either an ordered logistic regression or mixed model ordered logistic regression (Stata SE 16.1). Results: There were 344 survey responses (rate 64.3%). Mean age of the respondents was 57.5 years, 70.0% were women, 67.3% were Caucasian, and 25.4% were Black. Many patients (35.0%) did not attend college, and 5.0% had not finished high school. The median estimated income was ≥45,820. Ninety-six patients (30.0%) did not have adequate internet access for telehealth use with 6.5% not having any internet access at all. Participants scored an average of 57.4% correct on the technology knowledge quiz. In unadjusted analysis, technological knowledge was predicted by age (Fig A), race (Fig B), income (Fig C), education level (Fig D), and cell phone type (Fig E). The type of home internet access and was not predictive of quiz score. Age, race, education level, and cell phone type remained significantly predictive of technological knowledge in multivariable analysis (Fig F). Home internet access (p =0.416) and median income (p =0.109) were not significantly associated with quiz score. Conclusions: In our sample, nearly one-third of cancer patients did not have adequate internet access for telehealth. There were significant disparities in technological knowledge among cancer patients which were associated with demographic characteristics. This study provides information for identifying patients that may have barriers to successful utilization of telehealth.
Publisher Correction: Human–chimpanzee fused cells reveal cis-regulatory divergence underlying skeletal evolution
Authors: David Gokhman, Rachel M. Agoglia, Maia Kinnebrew, Wei Gordon, Danqiong Sun, Vivek K. Bajpai, Sahin Naqvi, Coral Chen, Anthony Chan, Chider Chen, Dmitri A. Petrov, Nadav Ahituv, Honghao Zhang, Yuji Mishina, Joanna Wysocka, Rajat Rohatgi, Hunter B. Fraser
Journal: Nature Genetics (2021)
Abstract 11249: Novel Rodent Model of Exercise-induced Pulmonary Hypertension (EIPH) in Heart Failure With Preserved Ejection Fraction
Authors: Taijyu Satoh, Longfei Wang, Charles F McTiernan, Andrea Levine, Scott Hahn, Jeff Baust, Samuel Wyman, Nathan Salamacha, Yijen L Wu, Cynthia St Hilaire, Dmitry Goncharova, Elena Goncharova, Adam C Straub, Yen Chun Lai, Mark T Gladwin
Journal: Circulation (2019)

Background: Exercise-induced pulmonary hypertension (EIPH) portends early stage PH. However, there are no rodent models of EIPH, and its pathogenesis remains unclear. We hypothesized that ZSF-1 rat...
IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression
Authors: Emmanuel Tharmarajah, April Buazon, Vishit Patel, Jennifer R. Hannah, Maryam Adas, Victoria B. Allen, Katie Bechman, Benjamin D. Clarke, Deepak Nagra, Sam Norton, Mark D. Russell, Andrew I. Rutherford, Mark Yates, James B. Galloway
Journal: Journal of Infection (2021)
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
Authors: Courtney D. DiNardo, Eytan M. Stein, Arnaud Pigneux, Jessica K. Altman, Robert Collins, Harry P. Erba, Justin M. Watts, Geoffrey L. Uy, Thomas Winkler, Hongfang Wang, Sung Choe, Hua Liu, Bin Wu, Stephanie M. Kapsalis, Gail J. Roboz, Stéphane de Botton
Journal: Leukemia (2021)
A genome-wide association study of LCH identifies a variant in
Authors: Erin C Peckham-Gregory, Rikhia Chakraborty, Michael E Scheurer, John W Belmont, Harshal Abhyankar, Amel G Sengal, Brooks P Scull, Olive Eckstein, Daniel J Zinn Md, Louisa Mayer, Albert Shih, Miriam Merad, D Williams Parsons, Kenneth L McClain, Philip J Lupo, Carl E Allen
Journal: Blood (2017)
P21.03 Dutch Lung Cancer Audit-Radiotherapy: Real-World Data on Stage III Non-Small Cell Lung Cancer Treated With Radiotherapy Only
Authors: L. Van Bockel, L. Van Der Woude, K. De Jaeger, I. Coremans, R. Damhuis, C. Van Es, A. Van Der Geest, D. Van Kampen, H.P. Knol, W. Kolff, F. Koppe, J. Pomp, B. Reymen, D. Schinagl, F. Spoelstra, C. Tissing-Tan, E. Vonk, N. Van Der Voort-Van Zijp, A. Van Der Wel, R. Wijsman, E. Wiegman, J. Belderbos
Journal: Journal of Thoracic Oncology (2021)
OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC
Authors: T. Owonikoko, M. Boyer, M. Johnson, R. Govindan, L. Rodrigues, F. Blackhall, R. Boosman, S. Champiat, H. Hummel, W.V. Lai, H. Udagawa, A. Chiang, A. Dowlati, C. Hann, R. Salgia, E. Vokes, M. Minocha, N. Sadraei, A. Shetty, M. Smit, Y. Zhang, B. Sable, A. Pati, S. Roy, H. Borghaei
Journal: Journal of Thoracic Oncology (2021)
Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?
Authors: Samy Suissa, Deborah Assayag
Journal: European Respiratory Journal (2021)

<b>Study from the INSIGHTS-IPF registry is affected by immortal time bias, which greatly exaggerates the reported effectiveness of pirfenidone and nintedanib on lowering mortality by 37% in patients with IPF.</b>https://bit.ly/2Xp7XTr
P61.02 MCL1 Inhibition Enhances the Therapeutic Effect of MEK Inhibitors in KRAS-Mutant Lung Adenocarcinoma Cells
Authors: M. Tada, T. Sumi, Y. Tanaka, S. Hirai, M. Yamaguchi, M. Miyajima, H. Takahashi, A. Watanabe, Y. Sakuma
Journal: Journal of Thoracic Oncology (2021)
P14.13 Notch Family Gene Mutations Predict Clinical Benefit from Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
Authors: H. Zhou, J. Shen, J. Liu, Y. Zhang, T. Zhou, S. Hong, Y. Zhao, Y. Yang, H. Zhao, Y. Huang, L. Zhang
Journal: Journal of Thoracic Oncology (2021)
Prediagnostic Inflammation and Pancreatic Cancer Survival
Authors: Chen Yuan, Vicente Morales-Oyarvide, Natalia Khalaf, Kimberly Perez, Fred K Tabung, Gloria Y F Ho, Charles Kooperberg, Aladdin H Shadyab, Lihong Qi, Peter Kraft, Howard D Sesso, Edward L Giovannucci, JoAnn E Manson, Meir J Stampfer, Kimmie Ng, Charles S Fuchs, Brian M Wolpin, Ana Babic
Journal: JNCI Journal of the National Cancer Institute (2021)

Chronic inflammation may promote initiation and progression of pancreatic cancer, but no studies have examined the association between inflammation in the period before diagnosis and pancreatic cancer survival.We prospectively examined the association of prediagnostic plasma levels of C-reactive protein, interleukin-6, and tumor necrosis factor-α receptor 2 with survival among 492 participants from 5 large US prospective cohort studies who developed pancreatic cancer. Using an empirical dietary inflammatory pattern (EDIP) score, we evaluated whether long-term proinflammatory diets were associated with survival among 1153 patients from 2 of the 5 cohorts. Cox proportional hazards regression was used to estimate hazard ratios for death with adjustment for potential confounders. All statistical tests were 2-sided.Higher prediagnostic levels of C-reactive protein, interleukin-6, and tumor necrosis factor-α receptor 2 were individually associated with reduced survival (Ptrend = .03, .01, and .04, respectively). Compared with patients with a combined inflammatory biomarker score of 0 (all 3 marker levels below medians), those with a score of 3 (all 3 marker levels above medians) had a hazard ratio for death of 1.57 (95% confidence interval = 1.16 to 2.12; Ptrend = .003), corresponding to median overall survival times of 8 vs 5 months. Patients consuming the most proinflammatory diets (EDIP quartile 4) in the prediagnostic period had a hazard ratio for death of 1.34 (95% confidence interval = 1.13 to 1.59; Ptrend = .01), compared with those consuming the least proinflammatory diets (EDIP quartile 1).Prediagnostic levels of inflammatory biomarkers and long-term proinflammatory diets were inversely associated with pancreatic cancer survival.
Abstract 15573: Initial Surgery versus Conservative Management of Chronic Severe Aortic Regurgitation in Mild Symptomatic Older Patients
Authors: Seung-Ah Lee, Sahmin Lee, Ho Jin Kim, Joon Bum Kim, Sung-Ho Jung, Suk Jung Choo, Jong-Min Song, Cheol-Hyun Chung, Duk-Hyun Kang, Jae-kwan Song, Jae-Won Lee, Dae-Hee Kim
Journal: Circulation (2019)

Background: The surgery (AVR) for severe aortic regurgitation (AR) should be balanced against operative risk. The mortality rate is lower in patients with mild symptoms than those with severe sympt...
Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study
Authors: Amyn A Malik, Saira Farooq, Maria Jaswal, Hiba Khan, Kumail Nasir, Usama Fareed, Shumail Shahbaz, Farhana Amanullah, Nauman Safdar, Aamir J Khan, Salmaan Keshavjee, Mercedes C Becerra, Hamidah Hussain
Journal: The Lancet Child & Adolescent Health (2021)